Vir Biotechnology, Inc.
VIR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001706431
No open-market purchases or sales by Vir Biotechnology, Inc. insiders were filed in the last 90 days; 237 institutions reported holding it in 13F filings for Q2 2026, worth $1.49B in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Vir Biotechnology, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 215 | 2 | 197 | −16 |
| Shares | 88.0M | 16.4M | 87.6M | +16.1M (+22.4%) |
| Value | $783.1M | $146.4M | $656.3M | +$19.5M (+3.1%) |
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (22)
Institutions that held Vir Biotechnology, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 16,375,806 | $122.7M | 0.00% |
| Jefferies Financial Group Inc. | 1,085,210 | $8.13M | 0.13% |
| Sofinnova Investments, Inc. | 129,246 | $968.1K | 0.08% |
| Allianz Asset Management GmbH | 72,356 | $541.9K | 0.00% |
| Verition Fund Management LLC | 52,794 | $395.4K | 0.00% |
| Colony Group, LLC | 46,434 | $347.8K | 0.00% |
| Valence8 US LP | 33,650 | $252.0K | 0.11% |
| Balyasny Asset Management LLC | 26,433 | $198.0K | 0.00% |
| Intech Investment Management LLC | 25,522 | $191.2K | 0.00% |
| Walleye Capital LLC | 23,776 | $178.1K | 0.00% |
| Sherbrooke Park Advisers LLC | 19,719 | $147.7K | 0.03% |
| Quantbot Technologies LP | 18,452 | $138.2K | 0.01% |
| Cerity Partners LLC | 16,435 | $123.1K | 0.00% |
| Captrust Financial Advisors | 15,820 | $118.5K | 0.00% |
| E Fund Management Co., Ltd. | 11,170 | $83.7K | 0.00% |
| nVerses Capital, LLC | 7,500 | $56.2K | 0.03% |
| Shell Asset Management Co | 5,045 | $38.0K | 0.00% |
| Sterling Capital Management LLC | 319 | $2.39K | 0.00% |
| Aster Capital Management (DIFC) Ltd | 178 | $1.33K | 0.00% |
| Bessemer Group Inc | 140 | $1.00K | 0.00% |
| GWM Advisors LLC | 20 | $150 | 0.00% |
| Mendota Financial Group, LLC | 6 | $45 | 0.00% |
Sold out (38)
Institutions that held Vir Biotechnology, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
Not filed for Q3 2024 yet (2)
Institutions that held Vir Biotechnology, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 16,434,122 | $146.3M |
| Susquehanna Fundamental Investments, LLC | 15,200 | $135.3K |